Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)-Reference-Cited by-同舟云学术

Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)

Published:2020-02-19 Issue:10 Volume:594 Page:1615-1623
ISSN:0014-5793
Container-title:FEBS Letters
language:en
Short-container-title:FEBS Lett

Author:

Takahashi Mizuki¹^ORCID,Ubukata Osamu²,Homma Tsuyoshi³,Asoh Yusuke⁴,Honzumi Masatoshi⁵,Hayashi Noriyuki⁶,Saito Keiji⁶,Tsuruoka Hiroyuki⁷,Aoki Kazumasa⁶,Hanzawa Hiroyuki¹^ORCID

Affiliation:

1. Structure‐Based Drug Design Group Organic Synthesis Department Daiichi Sankyo RD Novare Co., Ltd. Tokyo Japan

2. Protein Production Research Group Biological Research Department Daiichi Sankyo RD Novare Co., Ltd. Tokyo Japan

3. Global Project Management Department Daiichi Sankyo Co., Ltd. Tokyo Japan

4. IT Strategy Department Daiichi Sankyo Co., Ltd. Tokyo Japan

5. Process Technology Research Laboratories Daiichi Sankyo Co., Ltd. Kanagawa Japan

6. Medicinal Chemistry Research Laboratories Daiichi Sankyo Co., Ltd. Tokyo Japan

7. Intellectual property department Daiichi Sankyo Co., Ltd. Tokyo Japan

Publisher

Wiley

Subject

Cell Biology,Genetics,Molecular Biology,Biochemistry,Structural Biology,Biophysics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1873-3468.13746

Reference27 articles.

1. The role of spironolactone in the treatment of patients with refractory hypertension

2. Efficacy and Safety of the Selective Aldosterone Blocker Eplerenone in Japanese Patients With Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study

3. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

4. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

5. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex;Journal of the American Heart Association;2024-09-09

2. Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials;Frontiers in Pharmacology;2024-02-27

3. Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway;Biomedicines;2023-12-15

4. Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators;Steroids;2023-11

5. Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes;Diabetes, Obesity and Metabolism;2023-10-27